Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29546074
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Matrine Ameliorates Colorectal Cancer in Rats via Inhibition of HMGB1 Signaling
and Downregulation of IL-6, TNF-?, and HMGB1
#MMPMID29546074
Fan H
; Jiang C
; Zhong B
; Sheng J
; Chen T
; Chen Q
; Li J
; Zhao H
J Immunol Res
2018[]; 2018
(?): 5408324
PMID29546074
show ga
Matrine may be protective against colorectal cancer (CRC), but how it may work is
unclear. Thus, we explored the underlying mechanisms of matrine in CRC.
Matrine-related proteins and CRC-related genes and therapeutic targets of matrine
in CRC were predicted using a network pharmacology approach. Five targets,
including interleukin 6 (IL-6), the 26S proteasome, tumor necrosis factor alpha
(TNF-?), transforming growth factor beta 1 (TGF-?1) and p53, and corresponding
high-mobility group box 1 (HMGB1) signaling and T helper cell differentiation
were thought to be associated with matrine's mechanism. Expression of predicted
serum targets were verified in a 1,2-dimethylhydrazine dihydrochloride-induced
CRC model rats that were treated with matrine (ip) for 18 weeks. Data show that
matrine suppressed CRC growth and decreased previously elevated expression of
IL-6, TNF-?, p53, and HMGB1. Matrine may have had a therapeutic effect on CRC via
inhibition of HMGB1 signaling, and this occurred through downregulation of IL-6,
TNF-?, and HMGB1.
free
free
free
